A Randomized, Investigator- and Subject-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

Trial Profile

A Randomized, Investigator- and Subject-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Seletalisib (Primary)
  • Indications Immunological disorders; Plaque psoriasis; Sjogren's syndrome
  • Focus Adverse reactions
  • Sponsors UCB
  • Most Recent Events

    • 17 Jun 2017 Results of human PK profile (from two phase I studies) along with in-vitro cell-based studies on blood samples presented at the 18th Annual Congress of the European League Against Rheumatism
    • 04 Feb 2017 Results of two phase I studies (NCT02303509 and NCT02207595), published in the European Journal of Clinical Pharmacology
    • 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top